OncoMatch/Clinical Trials/NCT07106723
Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
Is NCT07106723 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies ASCT+CD7-CART for cd7 positive.
Treatment: ASCT+CD7-CART — To evaluate the safety and efficacy of autologous hematopoietic stem cell transfer (ASCT) combined with CD7-CART in the treatment of CD7+ TCL
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD7 expression
Confirmed as tumor cells expressing CD7 by histopathology and/or cytology at the time of screening
Allowed: TP53 deletion
high-risk factors, such as ... TP53 deletion/mutation
Allowed: TP53 mutation
high-risk factors, such as ... TP53 deletion/mutation
Allowed: RAS activating mutation
high-risk factors, such as ... RAS activating mutation
Disease stage
Required: Stage III, IV
Demographics
Prior therapy
Cannot have received: autologous hematopoietic stem cell transplant
Have a history of autologous/allogeneic hematopoietic stem cell transplantation
Cannot have received: allogeneic hematopoietic stem cell transplant
Have a history of autologous/allogeneic hematopoietic stem cell transplantation
Cannot have received: CAR-T cell therapy
Have used any CAR-T cell products or other genetically modified T-cell therapies
Cannot have received: CD7-targeted therapy
Received CD7-targeted therapy
Lab requirements
Blood counts
INR ≤ 1.5x ULN, aPTT ≤ 1.5x ULN
Kidney function
serum creatinine clearance rate ≥ 30 mL/min
Liver function
ALT and AST ≤ 3x ULN (≤ 5x ULN if due to disease); total serum bilirubin ≤ 2x ULN (≤ 3x ULN for Gilbert's syndrome, direct bilirubin ≤ 1.5x ULN)
Cardiac function
Left ventricular ejection fraction ≥ 50% by echocardiography; no clinically significant abnormal ECG findings; no clinically significant pericardial effusion and pleural effusion
With appropriate organ function: 1) ALT and AST ≤ 3x ULN (≤ 5x ULN if due to disease); 2) Total serum bilirubin ≤ 2x ULN, except for patients with Gilbert's syndrome; patients with Gilbert's syndrome and total bilirubin ≤ 3x ULN and direct bilirubin ≤ 1.5x ULN can be included; 3) Serum creatinine clearance rate ≥ 30 mL/min; 4) INR ≤ 1.5x ULN, and aPTT ≤ 1.5x ULN; 5) Possessing the minimum level of lung reserve, defined as ≤ grade 1 dyspnea (CTCAE v5.0) and non-oxygen-dependent blood oxygen saturation ≥ 92%; 6) Left ventricular ejection fraction ≥ 50% by echocardiography; no clinically significant abnormal electrocardiogram findings; no clinically significant pericardial effusion and pleural effusion.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07106723 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous hematopoietic stem cell transplant, allogeneic hematopoietic stem cell transplant, CAR-T cell therapy disqualifies patients from enrollment.
Does this trial require CD7?
Yes, CD7 expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages